Clinical Trial Update: A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of NK012 in advanced, metastatic triple-negative breast cancer has completed enrollment and analysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• NK012 (NK012)

Snippet

Sponsor: Nippon Kayaku Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED